477.10

0.95% -4.60

After Hours: 476.00 -1.10 -0.23%

Vertex Pharmaceuticals Inc (VRTX)

Overview News Price History Option Chain Financials Why VRTX Down? Discussions Forecast Stock Split

Vertex Pharmaceuticals Inc stock is traded at $477.10, with a volume of 944.71K. It is down -0.95% in the last 24 hours and down -3.95% over the past month. Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Previous Close:

$481.70

Open:

$480.67

24h Volume:

944.71K

Relative Volume:

0.64

Market Cap:

$121.09B

Revenue:

$12.34B

Net Income/Loss:

$4.34B

P/E Ratio:

28.28

EPS:

16.8685

Net Cash Flow:

$3.71B

1W Performance:

-0.05%

1M Performance:

-3.95%

6M Performance:

+1.53%

1Y Performance:

+4.43%

1-Day Range:

$469.87

$480.67

1-Week Range:

$469.87

$493.61

52-Week Range:

$362.50

$533.67

Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile

Name

Vertex Pharmaceuticals Inc

Sector

Healthcare (1079)

Industry

Biotechnology (598)

Phone

(617) 341-6393

Address

50 NORTHERN AVENUE, BOSTON, MA

Employee

6,400

Twitter

@VertexPharma

Next Earnings Date

2026-08-03

Latest SEC Filings

VRTX's Discussions on Twitter

Compare VRTX vs REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VRTX Vertex Pharmaceuticals Inc	477.10	121.57B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	762.63	69.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	853.82	55.61B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	187.53	39.98B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	316.01	33.81B	5.76B	514.49M	1.10B	4.4813

Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-26	Upgrade	Maxim Group	Hold → Buy
Mar-10-26	Initiated	Jefferies	Buy
Mar-10-26	Reiterated	Oppenheimer	Outperform
Feb-13-26	Upgrade	Oppenheimer	Perform → Outperform
Jan-28-26	Resumed	Barclays	Overweight
Jan-22-26	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jan-12-26	Upgrade	Bernstein	Mkt Perform → Outperform
Jan-07-26	Resumed	UBS	Buy
Jan-06-26	Upgrade	Wolfe Research	Peer Perform → Outperform
Dec-03-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-13-25	Initiated	Scotiabank	Sector Outperform
Sep-25-25	Upgrade	Leerink Partners	Market Perform → Outperform
Sep-03-25	Initiated	Raymond James	Mkt Perform
Aug-06-25	Upgrade	Wells Fargo	Equal Weight → Overweight
May-07-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-06-25	Downgrade	Leerink Partners	Outperform → Market Perform
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight
Feb-12-25	Upgrade	Canaccord Genuity	Sell → Hold
Feb-11-25	Upgrade	Canaccord Genuity	Sell → Hold
Jan-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Dec-20-24	Reiterated	H.C. Wainwright	Buy
Dec-19-24	Downgrade	Oppenheimer	Outperform → Perform
Dec-09-24	Upgrade	Jefferies	Hold → Buy
Nov-14-24	Initiated	Citigroup	Buy
Oct-16-24	Initiated	Scotiabank	Sector Perform
Oct-10-24	Resumed	Raymond James	Mkt Perform
Aug-05-24	Downgrade	Barclays	Overweight → Equal Weight
Jun-27-24	Initiated	Redburn Atlantic	Buy
Apr-11-24	Upgrade	Evercore ISI	In-line → Outperform
Feb-15-24	Initiated	Wolfe Research	Outperform
Feb-06-24	Downgrade	Evercore ISI	Outperform → In-line
Feb-02-24	Downgrade	Bernstein	Outperform → Mkt Perform
Jan-31-24	Downgrade	Maxim Group	Buy → Hold
Jan-31-24	Downgrade	Robert W. Baird	Neutral → Underperform
Jan-24-24	Downgrade	Canaccord Genuity	Hold → Sell
Dec-14-23	Reiterated	RBC Capital Mkts	Sector Perform
May-30-23	Initiated	William Blair	Outperform
May-04-23	Resumed	Piper Sandler	Overweight
Mar-21-23	Initiated	Bernstein	Outperform
Jan-18-23	Initiated	Canaccord Genuity	Hold
Jan-17-23	Upgrade	SVB Leerink	Mkt Perform → Outperform
Dec-19-22	Downgrade	Jefferies	Buy → Hold
Jul-13-22	Initiated	Cantor Fitzgerald	Overweight
Jun-01-22	Upgrade	Maxim Group	Hold → Buy
May-23-22	Initiated	SVB Leerink	Mkt Perform
May-06-22	Downgrade	Robert W. Baird	Outperform → Neutral
May-03-22	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Feb-03-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jan-27-22	Reiterated	JP Morgan	Overweight
Jan-27-22	Reiterated	Morgan Stanley	Underweight
Jan-27-22	Reiterated	RBC Capital Mkts	Outperform
Jan-27-22	Reiterated	Stifel	Hold
Jan-27-22	Reiterated	Wolfe Research	Outperform
Jan-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Dec-09-21	Initiated	Wells Fargo	Overweight
Nov-19-21	Initiated	BMO Capital Markets	Market Perform
Nov-19-21	Downgrade	Piper Sandler	Overweight → Neutral
Sep-09-21	Downgrade	Stifel	Buy → Hold
Sep-07-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jul-20-21	Downgrade	SVB Leerink	Mkt Perform → Underperform
Jul-19-21	Resumed	Wolfe Research	Outperform
Jul-01-21	Initiated	Raymond James	Mkt Perform
Jun-11-21	Downgrade	Daiwa Securities	Outperform → Neutral
Feb-23-21	Upgrade	Robert W. Baird	Neutral → Outperform
Feb-02-21	Reiterated	H.C. Wainwright	Buy
Dec-30-20	Initiated	Daiwa Securities	Outperform
Nov-30-20	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Nov-20-20	Initiated	Bernstein	Outperform
Oct-28-20	Initiated	UBS	Buy
Jul-31-20	Reiterated	H.C. Wainwright	Buy
Jul-08-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-30-20	Reiterated	H.C. Wainwright	Buy
Apr-28-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Mar-04-20	Initiated	Barclays	Overweight
Jan-31-20	Downgrade	Robert W. Baird	Outperform → Neutral
Nov-19-19	Upgrade	Guggenheim	Neutral → Buy
Nov-12-19	Initiated	SunTrust	Buy
Oct-17-19	Resumed	BofA/Merrill	Buy
Sep-03-19	Upgrade	Goldman	Neutral → Buy
Aug-01-19	Downgrade	Needham	Buy → Hold
May-23-19	Resumed	Citigroup	Buy
May-21-19	Initiated	Credit Suisse	Outperform
Apr-12-19	Initiated	Evercore ISI	In-line
Mar-26-19	Upgrade	William Blair	Mkt Perform → Outperform
Mar-19-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Feb-06-19	Downgrade	Maxim Group	Buy → Hold

View All

Vertex Pharmaceuticals Inc Stock (VRTX) Latest News

Jul 28, 2026

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Jul 28, 2026

Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees - The Motley Fool

Jul 28, 2026

Jul 27, 2026

Vertex Gears Up to Report Q2 Earnings: What Can Investors Expect? - TradingView

Jul 27, 2026

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Jul 27, 2026

Vertex Pharmaceuticals (VRTX) Projected to Announce Quarterly Earnings on Monday - MarketBeat

Jul 27, 2026

OMERS ADMINISTRATION Corp Has $8.39 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Jul 27, 2026

Lombard Odier Asset Management Switzerland SA Cuts Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Jul 27, 2026

Jul 26, 2026

Healthcare of Ontario Pension Plan Trust Fund Purchases 20,523 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Jul 26, 2026

Sei Investments Co. Sells 230,797 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Jul 26, 2026